Eledon’s Tegoprubart Hits Key Milestones in Transplant Trials
Event summary
- 100% insulin independence achieved in 10 type 1 diabetes patients post-islet transplant using tegoprubart.
- FDA grants Orphan Drug designation to tegoprubart for liver transplant rejection prevention.
- Cash reserves at $111.1M as of Q1 2026, down from $133.3M at year-end 2025.
- Phase 1b kidney transplant trial shows improved graft function with no rejection episodes.
- Net loss of $39.0M in Q1 2026, including $19.0M non-cash warrant liability charge.
The big picture
Eledon’s progress with tegoprubart underscores the growing potential of non-depleting immunomodulators in organ transplantation. The FDA designation for liver transplants expands its pipeline beyond kidney and islet cell applications, positioning the company as a key player in transplant medicine. With $111M in reserves, Eledon must balance aggressive clinical development against financial sustainability as it approaches potential Phase 3 trials.
What we're watching
- Regulatory Pathway
- Whether FDA guidance will accelerate tegoprubart’s Phase 3 kidney transplant trial initiation.
- Clinical Momentum
- The pace at which Eledon can translate positive islet transplant data into commercial opportunities.
- Financial Runway
- How Eledon manages cash burn while advancing multiple clinical programs through 2027.
Related topics